Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX)‘s stock had its “hold” rating restated by analysts at Piper Jaffray Companies in a report issued on Friday. They currently have a $14.00 price objective on the software maker’s stock. Piper Jaffray Companies’ target price points to a potential upside of 15.70% from the stock’s previous close.

Other analysts have also recently issued research reports about the stock. Maxim Group reiterated a “buy” rating and set a $16.00 target price on shares of Allscripts Healthcare Solutions in a research report on Monday, May 15th. Citigroup Inc. upgraded shares of Allscripts Healthcare Solutions from a “hold” rating to a “buy” rating in a research report on Friday, March 24th. They noted that the move was a valuation call. Deutsche Bank AG upgraded shares of Allscripts Healthcare Solutions from a “hold” rating to a “buy” rating and upped their target price for the company from $12.50 to $14.00 in a research report on Friday, March 24th. They noted that the move was a valuation call. Zacks Investment Research upgraded shares of Allscripts Healthcare Solutions from a “sell” rating to a “hold” rating in a research report on Wednesday, April 19th. Finally, BidaskClub upgraded shares of Allscripts Healthcare Solutions from a “sell” rating to a “hold” rating in a research report on Saturday, June 24th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and ten have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $14.74.

Shares of Allscripts Healthcare Solutions (NASDAQ MDRX) traded up 0.67% during trading on Friday, reaching $12.10. The company’s stock had a trading volume of 1,218,194 shares. The company’s 50-day moving average is $12.40 and its 200-day moving average is $12.04. Allscripts Healthcare Solutions has a 12 month low of $9.80 and a 12 month high of $15.17. The company’s market capitalization is $2.20 billion.

Allscripts Healthcare Solutions (NASDAQ:MDRX) last issued its earnings results on Thursday, May 4th. The software maker reported $0.10 EPS for the quarter, beating the consensus estimate of $0.09 by $0.01. The company had revenue of $415 million during the quarter, compared to analysts’ expectations of $415.20 million. Allscripts Healthcare Solutions had a negative net margin of 2.93% and a positive return on equity of 5.75%. The business’s revenue for the quarter was up 20.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.13 EPS. On average, analysts forecast that Allscripts Healthcare Solutions will post $0.62 EPS for the current fiscal year.

WARNING: This piece was first published by American Banking News and is the property of of American Banking News. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/07/21/allscripts-healthcare-solutions-inc-mdrx-rating-reiterated-by-piper-jaffray-companies.html.

In related news, President Richard J. Poulton sold 25,000 shares of the company’s stock in a transaction on Tuesday, May 16th. The shares were sold at an average price of $12.06, for a total value of $301,500.00. Following the completion of the transaction, the president now directly owns 412,488 shares of the company’s stock, valued at approximately $4,974,605.28. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.75% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently made changes to their positions in MDRX. Vanguard Group Inc. raised its position in shares of Allscripts Healthcare Solutions by 3.7% in the first quarter. Vanguard Group Inc. now owns 14,642,919 shares of the software maker’s stock worth $185,672,000 after buying an additional 519,798 shares during the last quarter. Iridian Asset Management LLC CT raised its position in shares of Allscripts Healthcare Solutions by 26.5% in the fourth quarter. Iridian Asset Management LLC CT now owns 13,268,624 shares of the software maker’s stock worth $135,473,000 after buying an additional 2,781,219 shares during the last quarter. Westpac Banking Corp raised its position in shares of Allscripts Healthcare Solutions by 0.7% in the third quarter. Westpac Banking Corp now owns 7,525,766 shares of the software maker’s stock worth $99,114,000 after buying an additional 54,701 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Allscripts Healthcare Solutions by 9.4% in the first quarter. Dimensional Fund Advisors LP now owns 7,227,789 shares of the software maker’s stock worth $91,648,000 after buying an additional 621,620 shares during the last quarter. Finally, First Trust Advisors LP raised its position in shares of Allscripts Healthcare Solutions by 111.5% in the fourth quarter. First Trust Advisors LP now owns 6,809,932 shares of the software maker’s stock worth $104,737,000 after buying an additional 3,590,772 shares during the last quarter.

About Allscripts Healthcare Solutions

Allscripts Healthcare Solutions, Inc (Allscripts) delivers information technology (IT) solutions and services to help healthcare organizations. The Company operates through three segments: Clinical and Financial Solutions, Population Health, and Netsmart. The Clinical and Financial Solutions segment includes the sale of integrated clinical software applications and financial and information solutions.

Analyst Recommendations for Allscripts Healthcare Solutions (NASDAQ:MDRX)

Receive News & Ratings for Allscripts Healthcare Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allscripts Healthcare Solutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.